Active substance
Results for the substance lutetium (177lu) vipivotide tetraxetane
1 result
About this active substance
Lutetium (177Lu) vipivotide tetraxetan is a radiopharmaceutical agent used in the treatment of certain types of cancer, particularly neuroendocrine tumors and prostate cancer. It works by delivering radiation directly to cancer cells, destroying them and reducing tumor size.
The medication is administered intravenously under the supervision of a nuclear medicine specialist. Treatment is typically carried out in multiple sessions, and patients are closely monitored to assess effectiveness and manage any side effects.
Side effects may include nausea, fatigue, decreased blood cell counts, and, in rare cases, kidney function impairment. It is important for patients to inform their doctor about any other treatments or medications they are taking.
Pregnant or breastfeeding women should not use this medication, and patients must follow all safety instructions provided by the medical team.
The medication is administered intravenously under the supervision of a nuclear medicine specialist. Treatment is typically carried out in multiple sessions, and patients are closely monitored to assess effectiveness and manage any side effects.
Side effects may include nausea, fatigue, decreased blood cell counts, and, in rare cases, kidney function impairment. It is important for patients to inform their doctor about any other treatments or medications they are taking.
Pregnant or breastfeeding women should not use this medication, and patients must follow all safety instructions provided by the medical team.